Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 78
Filter
1.
J Viral Hepat ; 22(3): 254-62, 2015 Mar.
Article in English | MEDLINE | ID: mdl-25081140

ABSTRACT

Triple therapy with telaprevir, pegylated interferon and ribavirin has been reported to improve antiviral efficacy but have potentially severe adverse effects in patients with chronic hepatitis C. To avoid the severe effects of telaprevir, lowering the dose has been suggested. However, impact of dosage changes on antiviral and adverse effects remains unclear. One hundred and sixty-six Japanese patients with HCV genotype 1 were treated with triple therapy. The drug exposure of each medication was calculated by averaging the dose actually taken. The overall SVR rate was 82%. The telaprevir discontinuation rate was 26%. The factors associated with discontinuation were an older age (≥65 y.o.) and a higher average dose during treatment. The telaprevir discontinuation rates were 42%, 25% and 14% in patients at ≥35, 25-35 and <25 mg/kg/day of telaprevir and 58% in older patients at ≥35 mg/kg/day of TVR. The factors associated with SVR were treatment-naïve, relapse to previous treatment, higher average telaprevir dose during treatment and completion of treatment. The SVR rate was higher, at 91%, in patients at 25-35 mg/kg/day of telaprevir than the 71% and 78% observed in those at <25 and ≥35 mg/kg/day of drug. In Japanese patients, a mean telaprevir dose of 25-35 mg/kg/day during treatment can augment its efficacy in triple therapy for patients with HCV genotype 1.


Subject(s)
Genotype , Hepacivirus/genetics , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Oligopeptides/administration & dosage , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Aged , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , Biopsy , Female , Hepatitis C, Chronic/pathology , Humans , Interferon alpha-2 , Interferon-alpha/adverse effects , Liver/pathology , Liver/virology , Male , Middle Aged , Oligopeptides/adverse effects , Polyethylene Glycols/adverse effects , Recombinant Proteins/adverse effects , Recombinant Proteins/therapeutic use , Retrospective Studies , Ribavirin/adverse effects , Risk Factors , Treatment Outcome , Viral Load
2.
J Viral Hepat ; 21(5): 357-65, 2014 May.
Article in English | MEDLINE | ID: mdl-24716638

ABSTRACT

Pegylated interferon (Peg-IFN) plus ribavirin combination therapy is effective in patients with hepatitis C virus (HCV) infection and normal alanine aminotransferase levels (NALT). However, it remains unclear whether the risk of hepatocellular carcinoma (HCC) incidence is actually reduced in virological responders. In this study, HCC incidence was examined for 809 patients with NALT (ALT ≤ 40 IU/mL) treated with Peg-IFN alpha-2b and ribavirin for a mean observation period of 36.2 ± 16.5 months. The risk factors for HCC incidence were analysed by Kaplan-Meier method and Cox proportional hazards model. On multivariate analysis among NALT patients, the risk of HCC incidence was significantly reduced in patients with sustained virological response (SVR) or relapse compared with those showing nonresponse (NR) (SVR vs NR, hazard ratio (HR): 0.16, P = 0.009, relapse vs NR, HR: 0.11, P = 0.037). Other risk factors were older age (≥65 years vs <60 years, HR: 6.0, P = 0.032, 60-64 vs <60 years, HR: 3.2, P = 0.212) and male gender (HR: 3.9, P = 0.031). Among 176 patients with PNALT (ALT ≤ 30 IU/mL), only one patient developed HCC and no significant risk factors associated with HCC development were found. In conclusion, antiviral therapy for NALT patients with HCV infection can lower the HCC incidence in responders, particularly for aged and male patients. The indication of antiviral therapy for PNALT (ALT ≤ 30 IU/mL) patients should be carefully determined.


Subject(s)
Alanine Transaminase/blood , Antiviral Agents/therapeutic use , Carcinoma, Hepatocellular/epidemiology , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Adult , Aged , Female , Hepatitis C, Chronic/pathology , Humans , Incidence , Interferon alpha-2 , Male , Middle Aged , Recombinant Proteins/therapeutic use , Retrospective Studies , Risk Factors
3.
J Viral Hepat ; 17(5): 336-44, 2010 May.
Article in English | MEDLINE | ID: mdl-19678893

ABSTRACT

Reducing the dose of drug affects treatment efficacy in pegylated interferon (Peg-IFN) and ribavirin combination therapy for patients with hepatitis C virus (HCV) genotype 1. The aim of this study was to investigate the impact of drug exposure, as well as the baseline factors and the virological response on the treatment efficacy for genotype 2 patients. Two-hundred and fifty patients with genotype 2 HCV who were to undergo combination therapy for 24 weeks were included in the study, and 213 completed the treatment. Significantly more patients who achieved a rapid virological response (RVR), defined as HCV RNA negativity at week 4, achieved a sustained virological response (SVR) (92%, 122/133) compared with patients who failed to achieve RVR (48%, 38/80) (P < 0.0001). Multivariate logistic-regression analysis showed that only platelet counts [odds ratio (OR), 1.68; confidence interval (CI), 1.002-1.139] and RVR (OR, 11.251; CI, 5.184-24.419) were independently associated with SVR, with no correlation being found for the mean dose of Peg-IFN and ribavirin for RVR and SVR. Furthermore, in the stratification analysis of the timing of viral clearance, neither mean dose of Peg-IFN (P = 0.795) nor ribavirin (P = 0.649) affected SVR in each group. Among the patients with RVR, the lowest dose group of Peg-IFN (0.77 +/- 0.10 microg/kg/week) and ribavirin (6.9 +/- 0.90 mg/kg/day) showed 100% and 94% of SVR. Hence, RVR served as an important treatment predictor, and drug exposure had no impact on both SVR and RVR in combination therapy for genotype 2 patients.


Subject(s)
Antiviral Agents/administration & dosage , Hepacivirus/classification , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha/administration & dosage , Polyethylene Glycols/administration & dosage , Ribavirin/administration & dosage , Adult , Aged , Drug Therapy, Combination , Female , Genotype , Hepacivirus/genetics , Humans , Interferon alpha-2 , Male , Middle Aged , Platelet Count , RNA, Viral/blood , Recombinant Proteins , Treatment Outcome , Viral Load
4.
J Viral Hepat ; 16(8): 586-94, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19552664

ABSTRACT

The impact of ribavirin exposure on virologic relapse remains controversial in combination therapy with pegylated interferon (Peg-IFN) and ribavirin for patients with chronic hepatitis C (CH-C) genotype 1. The present study was conducted to investigate this. Nine hundred and eighty-four patients with CH-C genotype 1 were enrolled. The drug exposure of each medication was calculated by averaging the dose actually taken. For the 472 patients who were HCV RNA negative at week 24 and week 48, multivariate logistic regression analysis showed that the degree of fibrosis (P = 0.002), the timing of HCV RNA negativiation (P < 0.001) and the mean doses of ribavirin (P < 0.001) were significantly associated with relapse, but those of Peg-IFN were not. Stepwise reduction of the ribavirin dose was associated with a stepwise increase in relapse rate from 11% to 60%. For patients with complete early virologic response (c-EVR) defined as HCV RNA negativity at week 12, only 4% relapse was found in patients given > or = 12 mg/kg/day of ribavirin and ribavirin exposure affected the relapse even after treatment week 12, while Peg-IFN could be reduced to 0.6 microg/kg/week after week 12 without the increase of relapse rate. Ribavirin showed dose-dependent correlation with the relapse. Maintaining as high a ribavirin dose as possible (> or = 12 mg/kg/day) during the full treatment period can lead to suppression of the relapse in HCV genotype 1 patients responding to Peg-IFN alpha-2b plus ribavirin, especially in c-EVR patients.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/isolation & purification , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Aged , Dose-Response Relationship, Drug , Female , Genotype , Hepacivirus/genetics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Middle Aged , Polyethylene Glycols/administration & dosage , RNA, Viral/blood , Recombinant Proteins , Recurrence , Ribavirin/administration & dosage , Treatment Outcome
5.
J Viral Hepat ; 16(8): 578-85, 2009 Aug.
Article in English | MEDLINE | ID: mdl-19552663

ABSTRACT

Chronic hepatitis C (CH-C) genotype 1 patients who achieved early virologic response have a high probability of sustained virologic response (SVR) following pegylated interferon (Peg-IFN) plus ribavirin therapy. This study was conducted to evaluate how reducing drug doses affects complete early virologic response (c-EVR) defined as hepatitis C virus (HCV) RNA negativity at week 12. Nine hundred eighty-four patients with CH-C genotype 1 were enrolled. Drug doses were evaluated independently on a body weight base from doses actually taken. From multivariate analysis, the mean dose of Peg-IFN alpha-2b during the first 12 weeks was the independent factor for c-EVR (P = 0.02), not ribavirin. The c-EVR rate was 55% in patients receiving > or = 1.2 microg/kg/week of Peg-IFN, and declined to 38% at 0.9-1.2 microg/kg/week, and 22% in patients given <0.9 microg/kg/week (P < 0.0001). Even with stratified analysis according to ribavirin dose, the dose-dependent effect of Peg-IFN on c-EVR was observed, and similar c-EVR rates were obtained if the dose categories of Peg-IFN were the same. Furthermore, the mean dose of Peg-IFN during the first 12 weeks affected HCV RNA negativity at week 24 (P < 0.0001) and SVR (P < 0.0001) in a dose-dependent manner. Our results suggest that Peg-IFN was dose-dependently correlated with c-EVR, independently of ribavirin dose. Thus, maintaining the Peg-IFN dose as high as possible during the first 12 weeks can yield HCV RNA negativity and higher c-EVR rates, leading to better SVR rates in patients with CH-C genotype 1.


Subject(s)
Antiviral Agents/therapeutic use , Hepacivirus/isolation & purification , Hepatitis C, Chronic/drug therapy , Hepatitis C, Chronic/virology , Interferon-alpha/therapeutic use , Polyethylene Glycols/therapeutic use , Ribavirin/therapeutic use , Aged , Dose-Response Relationship, Drug , Female , Genotype , Hepacivirus/genetics , Humans , Interferon alpha-2 , Interferon-alpha/administration & dosage , Male , Middle Aged , Polyethylene Glycols/administration & dosage , RNA, Viral/blood , Recombinant Proteins , Treatment Outcome
6.
Clin Nutr ; 23(5): 1060-8, 2004 Oct.
Article in English | MEDLINE | ID: mdl-15380896

ABSTRACT

Total parenteral nutrition (TPN) is associated with cholestasis and hepatic steatosis, which can be lethal in infants who cannot be fed orally. The present animal study focused on the metabolic complications in the liver that may occur due to the excessive administration of fat-free TPN. Thirty infant (3-week-old) male SD rats weighing 60-70 g were randomly allocated to five groups (n = 6): the OD group received an oral diet, the FT group received an oral diet and was fasted overnight on the last day of experiment before sacrifice, the 0% fat group received TPN without fat, the 20% fat group received TPN with 20% of calories from fat emulsion, and the 40% fat group received TPN with 40% of calories from fat emulsion. All TPN regimens were isocaloric, isonitrogenic, and administered for 4 days. In the 0% fat group, plasma levels of liver enzymes were significantly higher than in the other groups. Pathological examination showed hepatomegaly and severe fatty changes without cholestasis in the 0% fat group. The results of this study in infant rats indicate the importance of including fat in the TPN regimen in order to prevent the abnormal hepatic changes associated with the excessive administration of fat-free TPN.


Subject(s)
Fat Emulsions, Intravenous/administration & dosage , Lipid Metabolism , Liver/metabolism , Parenteral Nutrition, Total/adverse effects , Alanine Transaminase/metabolism , Animals , Animals, Newborn , Aspartate Aminotransferases/metabolism , Dose-Response Relationship, Drug , Fatty Acids/metabolism , Liver/drug effects , Liver/enzymology , Liver/pathology , Male , Organ Size , Random Allocation , Rats , Rats, Sprague-Dawley
7.
J Am Chem Soc ; 123(50): 12686-7, 2001 Dec 19.
Article in English | MEDLINE | ID: mdl-11741437
8.
J Cardiovasc Pharmacol ; 36(5 Suppl 1): S252-4, 2000 Nov.
Article in English | MEDLINE | ID: mdl-11078390

ABSTRACT

Endothelin (ET) receptor subtypes in human prostate with benign prostatic hyperplasia were investigated by binding and functional studies. In the displacement experiment, LU224332 [endothelin-A/-B (ET(A)/ET(B)) nonselective antagonist] competed for [125I]ET-1 binding with a monophasic curve. On the other hand, LU135252 (ET(A)-selective antagonist) and sarafotoxin S6c (S6c, ET(B)-selective agonist) competed for [125I]ET-1 binding with shallow and biphasic curves. The analysis of the displacement curves for LU135252 and S6c showed that both ET(A) and ET(B) subtypes coexist but that ET(A) is the dominantly expressed receptor. In human prostate strips, 10 microM of both LU135252 and LU224332 strongly inhibited the contractile response to ET-1 with equal potency. However, 10 microM of BQ788 (ET(B)-selective antagonist) did not show a clear inhibition. S6c also produced a contractile response, which was potently inhibited by LU224332 or BQ788, and slightly suppressed by LU135252. These results suggest that in human prostate both ET(A) and ET(B) subtypes are functional receptors mediating contraction, but that ET-1-mediated contractions are predominantly mediated by activation of dominant receptor subtype, ET(A).


Subject(s)
Prostate/chemistry , Receptors, Endothelin/analysis , Aged , Aged, 80 and over , Endothelin-1/pharmacology , Humans , Male , Middle Aged , Norepinephrine/pharmacology , Propionates/pharmacology , Prostate/drug effects , Prostate/physiology , Pyrimidines/pharmacology , Radioligand Assay , Receptor, Endothelin A , Receptor, Endothelin B , Receptors, Endothelin/physiology , Viper Venoms/pharmacology
9.
Pharmacology ; 60(4): 188-94, 2000 May.
Article in English | MEDLINE | ID: mdl-10828743

ABSTRACT

Electrical transmural stimulation evoked a sympathetic contraction in the isolated dog saphenous vein. This contraction consisted of three components (alpha(1)-adrenergic, alpha(2)-adrenergic and purinergic), which were separately observed under combined treatments either with yohimbine (blockade of alpha(2)-adrenoceptor) and alpha,beta-methylene ATP (desensitization of P(2X)-purinoceptors), with prazosin (blockade of alpha(1)-adrenoceptor) and alpha,beta-methylene ATP, or with prazosin and yohimbine, respectively. The alpha(1)-adrenergic and purinergic contractions immediately developed after the start of stimulation and reached a peak rapidly. In contrast, the alpha(2)-adrenergic contraction developed slowly, thus the time to peak contraction was longer than the other two components. The relationship between the peak amplitudes of contraction and stimulus frequencies were similar between alpha(1)- and alpha(2)-adrenergic components, but the purinergic contraction was smaller than the other components at all frequencies (0.1-30 Hz). Cocaine, a neuronal uptake inhibitor of noradrenaline, significantly potentiated alpha(1)- and alpha(2)-adrenergic components and prolonged their duration with a relatively greater effect on the alpha(2)-adrenergic component. In contrast, the purinergic component was not affected by cocaine. Exogenous noradrenaline produced concentration-dependent contraction, which was inhibited more effectively after combined treatment with combination of prazosin and yohimbine than either blocker given alone. Cocaine potentiated the attenuated contractile response to noradrenaline in the presence of prazosin, resulting in the recovery of response to the control level. Exogenous ATP produced a transient contraction, which was abolished under conditions where postjunctional P(2X)-purinoceptors were desensitized with alpha,beta-methylene ATP. Cocaine did not affect the ATP-induced contraction. These results suggest that sympathetic contraction of the dog saphenous vein is caused through three distinct routes (alpha(1)- and alpha(2)-adrenoceptors and P(2X)-purinoceptors).


Subject(s)
Adenosine Triphosphate/analogs & derivatives , Adrenergic alpha-Antagonists/pharmacology , Receptors, Adrenergic, alpha-1/drug effects , Receptors, Adrenergic, alpha-2/drug effects , Receptors, Purinergic/drug effects , Saphenous Vein/drug effects , Adenosine Triphosphate/metabolism , Adenosine Triphosphate/pharmacology , Animals , Dogs , Electric Stimulation , Female , Male , Norepinephrine/metabolism , Prazosin/pharmacology , Receptors, Adrenergic, alpha-1/physiology , Receptors, Adrenergic, alpha-2/physiology , Receptors, Purinergic/physiology , Saphenous Vein/chemistry , Saphenous Vein/physiology , Yohimbine/pharmacology
10.
Hepatology ; 31(4): 890-8, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10733545

ABSTRACT

Recent advances in imaging modalities enable the identification of small hepatocellular nodules. Among the imaging techniques currently used for detecting hepatocellular carcinomas (HCC), computed tomography (CT) during arterial portography (CTAP) is one of the most sensitive techniques available for detecting hemodynamic change. Even so, well-differentiated HCCs that display only limited hemodynamic change, a feature shared with nonmalignant hepatocellular nodules, are not always detectable by CTAP. To improve our ability to distinguish well-differentiated HCCs from nonmalignant hepatocellular nodules, we have attempted to clarify how the characteristics of the nodules are shown by each imaging technique. We studied the imaging and pathological characteristics of 31 nodules (in 22 patients) detected by ultrasonography (US), but not by CTAP. Histological diagnoses were as follows: HCC, 17 of 31 nodules (55%); high-grade dysplastic nodules, 1 of 31 (3%); and nonmalignant nodules, 13 of 31 (42%). Neither digital substraction angiography (DSA) nor CT arteriography (CTA) were able to detect any of the nodules. Detection rates for plain CT were: 5 of 17 (29%) HCC, 1 of 1 (100%) high-grade dysplastic nodules, and 1 of 13 (8%) nonmalignant nodules. Detection rates for T1/T2-weighted magnetic resonance imaging (MRI) were: 4 of 17 (24%) HCC, 1 of 1 (100%) high-grade dysplastic nodules, and 3 of 13 (23%) nonmalignant nodules. Dynamic CT and dynamic MRI provided no additional information. In conclusion, there is some probability that hepatocellular nodules detected by US, but not by CTAP, are HCC. Presently, it is difficult to distinguish between benign nodules and malignant ones with these imaging techniques, and our findings indicate that biopsy may be advisable for nodules detected under these conditions.


Subject(s)
Biomarkers , Carcinoma, Hepatocellular/diagnosis , Liver Neoplasms/diagnosis , Liver/pathology , Portography , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor/blood , Carcinoma, Hepatocellular/diagnostic imaging , Carcinoma, Hepatocellular/pathology , Female , Humans , Liver Neoplasms/diagnostic imaging , Liver Neoplasms/pathology , Magnetic Resonance Imaging , Male , Middle Aged , Protein Precursors/metabolism , Prothrombin/metabolism , Sensitivity and Specificity , Ultrasonography , alpha-Fetoproteins/analysis
11.
Gan To Kagaku Ryoho ; 26(13): 2077-80, 1999 Nov.
Article in Japanese | MEDLINE | ID: mdl-10584575

ABSTRACT

A patient with stage IVb advanced gastric cancer, who was Group 4 lymph node metastasis positive, underwent two postoperative courses of low-dose CDDP-tegafur therapy (800 mg/body/day of tegafur + 5 mg/body/5 administrations, 2 days of rest, of cisplatin). UFTP therapy (400 mg/body/day of UFT + 5 mg/body/twice weekly of cisplatin) was thereafter given on an outpatient basis. The patient has now been receiving this therapy for one year and six months. The anti-tumor effect has been maintained and the tumor has been reduced in size by 89% without any adverse reactions. A good QOL has been observed. The present therapy can be performed safely at home and appears to be a favorable treatment from the viewpoint of QOL.


Subject(s)
Adenocarcinoma/drug therapy , Antineoplastic Combined Chemotherapy Protocols/administration & dosage , Quality of Life , Stomach Neoplasms/drug therapy , Adenocarcinoma/secondary , Adenocarcinoma/surgery , Adult , Antineoplastic Combined Chemotherapy Protocols/therapeutic use , Cisplatin/administration & dosage , Drug Administration Schedule , Female , Humans , Lymphatic Metastasis , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Tegafur/administration & dosage , Uracil/administration & dosage
12.
J Viral Hepat ; 6(6): 463-9, 1999 Nov.
Article in English | MEDLINE | ID: mdl-10607265

ABSTRACT

Recently, the genome of a novel DNA virus, transfusion-transmitted virus (TTV), was cloned from the plasma of a blood donor who had an elevated aminotransferase level but no serological markers of known hepatitis viruses. In this study, we investigated the influence of TTV infection on the clinical features and response to interferon (IFN) therapy in patients with chronic hepatitis C. We studied 247 patients who had received a 16- or a 24-week course of IFN-alpha therapy. The serum of these patients was analysed for TTV DNA using a hemi-nested polymerase chain reaction and TTV was detected in 114 patients (46%). No significant differences were found with respect to clinical features (gender, age, liver-related biochemical tests, hepatitis C virus (HCV) genotype and serum HCV RNA levels) between the patients who were positive for TTV DNA and those who were negative for TTV DNA. The fibrosis score was higher in TTV-positive patients (2.1 +/- 1.1) than in TTV-negative patients (1.7 +/- 1.1, P = 0.023). The biochemical sustained-response rate was 25% in TTV-positive patients and 25% in TTV-negative patients (not significant). A sustained HCV clearance rate was achieved in 26% of TTV-positive patients and in 22% of TTV-negative patients (not significant). TTV DNA clearance after IFN therapy was observed in 36 of 69 patients (52%) for whom stored serum samples were available. The disappearance of TTV DNA had no effect on the biochemical response to IFN therapy. In conclusion, TTV co-infection is frequently observed in Japanese patients with chronic hepatitis C. In chronic hepatitis C, TTV does not modify the clinical features or the response to IFN.


Subject(s)
Antiviral Agents/therapeutic use , DNA Virus Infections/complications , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/drug therapy , Interferon-alpha/therapeutic use , Adolescent , Adult , Aged , DNA Virus Infections/virology , DNA Viruses/isolation & purification , DNA, Viral/blood , Female , Hepacivirus/isolation & purification , Hepatitis C, Chronic/pathology , Humans , Japan , Male , Middle Aged , Polymerase Chain Reaction , RNA, Viral/blood
13.
Endoscopy ; 31(7): 528-35, 1999 Sep.
Article in English | MEDLINE | ID: mdl-10533736

ABSTRACT

BACKGROUND AND STUDY AIMS: The aim of the present study was to evaluate a new endoscope disinfector (WM-1) that uses acidic electrolytic water (AEW). MATERIALS AND METHODS: AEW was produced by electrolysis of a 0.05% NaCl-water mixture, with a redox potential greater than 1000 mV and a pH lower than 2.7. In the first study, an endoscope artificially contaminated with 15 species of bacteria and four strains of viruses was treated using the WM-1. In the second study, endoscopic contamination after clinical use was examined by culture for Helicobacter pylori and other bacteria, and by polymerase chain reaction for the H. pylori urease gene and hepatitis C virus. The extent of contamination was then examined after exposing the WM-1 to AEW. The safety of AEW was examined using both in vivo and in vitro studies. RESULTS: All of the bacteria and viruses were destroyed or inactivated after the instrument had been exposed to AEW. Clinical contamination was detected from the instrument in 19 of 30 endoscopic procedures, whereas no bacteria or viruses were detected after five minutes' exposure to AEW. AEW was found to be nonirritant, nontoxic to cells, and nonmutagenic. CONCLUSION: The WM-1 successfully and safely disinfected the endoscopes. With running costs of yen 24 per day ($0.21 per day), the WM-1 provides an effective and inexpensive alternative to conventional disinfection equipment.


Subject(s)
Disinfectants , Disinfection/methods , Endoscopes , Equipment Contamination , Acids , Animals , Disinfection/instrumentation , Endoscopy, Gastrointestinal , Evaluation Studies as Topic , Male , Rabbits , Water
14.
Eur J Pharmacol ; 366(1): 119-26, 1999 Jan 29.
Article in English | MEDLINE | ID: mdl-10064160

ABSTRACT

The alpha1-adrenoceptor subtypes of rat prostate were characterized in binding and functional experiments. In binding experiments, [3H]tamsulosin bound to a single class of binding sites with an affinity (pKD) of 10.79+/-0.04 and Bmax of 87+/-2 fmol mg(-1) protein. This binding was inhibited by prazosin, 2-(2,6-dimethoxy-phenoxyethyl)-aminomethyl-1,4-benzodioxane hydrochloride (WB4101), 5-methylurapidil, alpha-ethyl-3,4,5,-trimethoxy-alpha-(3-((2-(2-methoxyphenoxy)ethyl)-amin o)-propyl)benzeneacetonitrile fumarate (HV723) and oxymetazoline with high efficacy, resulting in a good correlation with the binding characteristics of cloned alpha1a but not alpha1b and alpha1d-adrenoceptor subtypes. In functional studies, noradrenaline and oxymetazoline produced concentration-dependent contractions. These contractions were antagonized by tamsulosin, prazosin, WB4101 and 5-methylurapidil with an efficacy lower than that exhibited by these agents for inhibition of [3H]tamsulosin binding. The relationship between receptor occupancy and contractile amplitude revealed the presence of receptor reserve for noradrenaline, but the contraction induced by oxymetazoline was not in parallel with receptor occupation and developed after predicted receptor saturation. From these results, it is suggested that alpha1A-adrenoceptors are the dominant subtype in the rat prostate which can be detected with [3H]tamsulosin, but that the functional subtype mediating adrenergic contractions has the characteristics of the alpha1L-adrenoceptor subtype, having a lower affinity for prazosin and some other drugs than the alpha1A-adrenoceptor subtype.


Subject(s)
Prostate/metabolism , Receptors, Adrenergic, alpha-1/metabolism , Acetonitriles/pharmacology , Adrenergic alpha-1 Receptor Antagonists , Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Animals , Binding, Competitive/drug effects , Dioxanes/pharmacology , Dose-Response Relationship, Drug , In Vitro Techniques , Kinetics , Male , Muscle Contraction/drug effects , Norepinephrine/pharmacology , Oxymetazoline/pharmacology , Piperazines/pharmacology , Prazosin/pharmacology , Prostate/drug effects , Radioligand Assay , Rats , Rats, Sprague-Dawley , Sulfonamides/metabolism , Tamsulosin , Tritium
15.
Brain Res ; 798(1-2): 18-24, 1998 Jul 06.
Article in English | MEDLINE | ID: mdl-9666062

ABSTRACT

Several recent studies have defined a relationship between apo-lipoprotein E (apoE) genotype and the risk of various neurodegenerative disorders. However, few studies have examined the influence of apoE on quantitative measures of beta-amyloid (Abeta) accumulation in a large population of autopsy cases. Using a multi-level analysis model, the interrelationships among apoE genotype, gender, age, and Abeta accumulation were investigated. In the population of these cases, there was a strong relationship between the presence of an epsilon4 allele and extent of Abeta in the frontal and entorhinal cortex. That is, when evaluating the presence or absence of significant Abeta (>1% Abeta load), subjects with one and two epsilon4 alleles were 1.9 and 3.5 times more likely to have significant Abeta accumulation than those with no epsilon4 alleles. These risks increased by a multiplicative factor of 1.014 for each year of age (at the time of death). In the subset of cases with significant Abeta (>1% Abeta load), the degree of Abeta load was best predicted by the presence of an epsilon2 allele and gender; females with no epsilon2 alleles had the highest Abeta loads (mean=12.3%), while males with one epsilon2 allele had the lowest amount of Abeta accumulation (mean=8.6%). Our results suggest that the presence of an epsilon4 allele predicts an earlier onset of Abeta deposition that is independent of gender. In contrast, once Abeta deposition has been initiated, the presence of an epsilon2 allele is associated with slower rates of accumulation, with males benefiting from the protective effect more than females.


Subject(s)
Aging/metabolism , Amyloid beta-Peptides/metabolism , Apolipoproteins E/metabolism , Entorhinal Cortex/metabolism , Frontal Lobe/metabolism , Sex Characteristics , Adult , Aged , Aged, 80 and over , Apolipoprotein E2 , Apolipoprotein E4 , Entorhinal Cortex/pathology , Female , Frontal Lobe/pathology , Humans , Male , Middle Aged
16.
J Med Virol ; 55(2): 98-102, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9598928

ABSTRACT

A novel virus (GBV-C/HGV) may be associated with some liver diseases including fulminant hepatitis and acute and chronic hepatitis. On the other hand, many investigations showed that this infection does not contribute to liver disease. GBV-C/HGV has been found to occur in association with infection with other hepatitis viruses. We investigated the effect of GBV-C/HGV infection on the clinical features and interferon treatment in patients with chronic hepatitis C. A total of 262 hepatitis C virus (HCV) RNA positive patients with chronic hepatitis were examined in this study. The detection of serum GBV-C/HGV RNA was done by RT-PCR using specific primers from the NS5 regions. Interferon-alpha was given at a dose of 6 MU/day for 16 or 24 weeks. A responder was defined as a patient with ALT normalization and HCV RNA disappearance after treatment. GBV-C/HGV RNA was detected in 28 (11%) patients. No significant difference was detected in clinical features (age, sex, liver-related biochemical tests, and histological examination) between the 28 GBV-C/HGV-positive patients and the GBV-C/HGV-negative patients. Using interferon therapy for hepatitis C, the responder rates of GBV-C/HGV-positive and -negative patients were 14% and 20%, respectively. Of the 28 patients with GBV-C/HGV RNA, GBV-C/HGV RNA was tested after interferon therapy in 16 and of these GBV-C/HGV RNA was not detected in nine patients after therapy. These findings suggest that GBV-C/HGV infection dose not affect the clinical features in patients with HCV and the efficacy of interferon therapy for chronic hepatitis C.


Subject(s)
Flaviviridae/physiology , Hepatitis C, Chronic/physiopathology , Hepatitis C, Chronic/therapy , Hepatitis, Viral, Human/therapy , Interferon-alpha/therapeutic use , Adolescent , Adult , Aged , Female , Flaviviridae/genetics , Hepatitis C, Chronic/complications , Hepatitis C, Chronic/virology , Hepatitis, Viral, Human/complications , Hepatitis, Viral, Human/physiopathology , Hepatitis, Viral, Human/virology , Humans , Male , Middle Aged , RNA, Viral
17.
Life Sci ; 62(17-18): 1461-5, 1998.
Article in English | MEDLINE | ID: mdl-9585119

ABSTRACT

The subtypes of alpha1-adrenoceptor are coexpressed in many tissues. We examined the relationship between coexpressed alpha1-adrenoceptor subtypes and their functions in blood vessels. Rat and rabbit aortas coexpressed three subtypes (alpha1A, alpha1B, alpha1D) and four subtypes (alpha1A, alpha1B, alpha1D, alpha1L), respectively. In rat aorta however, noradrenaline-induced contraction was mediated predominantly through the alpha1D subtype, and oxymetazoline produced alpha1B-mediated contraction. In rabbit aorta, concentration-response curves for noradrenaline were composed of two components (alpha1B and alpha1L-mediated), while oxymetazoline produced alpha1L-mediated contraction. Therefore, the inhibitory actions of some antagonists varied markedly among tissues and agonists. These results demonstrate diversity of the two receptor systems and suggest that the heterogeneity of physiological responses reflects the differences in functional subtypes among tissues and in their sensitivities to agonists and antagonists.


Subject(s)
Muscle, Smooth, Vascular/physiology , Muscle, Smooth, Vascular/ultrastructure , Receptors, Adrenergic, alpha-1/classification , Receptors, Adrenergic, alpha-1/physiology , Adrenergic alpha-Agonists/pharmacology , Adrenergic alpha-Antagonists/pharmacology , Animals , Aorta, Thoracic/drug effects , Aorta, Thoracic/physiology , Aorta, Thoracic/ultrastructure , COS Cells , In Vitro Techniques , Kinetics , Muscle Contraction/drug effects , Muscle Contraction/physiology , Muscle, Smooth, Vascular/drug effects , Norepinephrine/pharmacology , Oxymetazoline/pharmacology , Rabbits , Rats , Receptors, Adrenergic, alpha-1/drug effects
18.
Nihon Rinsho ; 55(3): 617-20, 1997 Mar.
Article in Japanese | MEDLINE | ID: mdl-9086769

ABSTRACT

Hepatitis G virus(HGV) has been cloned and it is associated with liver diseases. We reported the influence of HGV infection on clinical features of patients with chronic hepatitis C. Subjects were 262 patients with HCV RNA. Detection of HGV RNA was performed by RT-PCR using specific primers from the NS5 regions. Of 262 patients, 28(11%) were positive HGV. No significant differences were detected in liver functions tests, histological examination and efficacy of interferon treatment between HGV-positive and HGV-negative patients with chronic hepatitis C. In conclusions, HGV infection did not influence clinical features of patients with chronic HCV infection.


Subject(s)
Flaviviridae , Hepatitis C/complications , Hepatitis, Viral, Human/complications , Adult , Biomarkers/blood , Chronic Disease , Female , Flaviviridae/genetics , Flaviviridae/isolation & purification , Hepatitis C/therapy , Hepatitis C/virology , Hepatitis, Viral, Human/therapy , Hepatitis, Viral, Human/virology , Humans , Interferons/therapeutic use , Male , Middle Aged , RNA, Viral/blood
19.
J Hepatol ; 26(3): 574-83, 1997 Mar.
Article in English | MEDLINE | ID: mdl-9075665

ABSTRACT

BACKGROUND/AIMS/METHODS: The imbalance between matrix metalloproteinases (MMPs) and tissue inhibitors of matrix metalloproteinases (TIMPs) is considered to be an important determinant of extracellular matrix deposition and breakdown. We measured serum MMP-1, MMP-2, TIMP-1 and TIMP-2 levels using the respective one-step sandwich enzyme immunoassays in 98 patients with chronic hepatitis C treated with interferon beta to examine their clinical significance for assessment of liver histology and to determine whether they can be useful as predictors of the interferon response. RESULTS: Serum TIMP-1 levels showed a positive correlation with the degree of fibrosis (r(s)=0.30, p= 0.004). Serum MMP-2 levels revealed positive relationships with the degree of periportal necrosis (r(s)= 0.32, p=0.002), the degree of fibrosis (r(s)=0.26, p= 0.01) and total score of histological activity index (r(s)=0.24, p=0.02). Serum MMP-2 levels were significantly higher in patients with no response than in those with sustained and transient response (p<0.01 and p<0.05, respectively), while serum MMP-1 levels did not differ among the three groups. Compared with the levels in sustained responders, the total amounts of serum TIMP-1 were significantly lower in transient responders and non-responders (p<0.01 and p<0.001, respectively). As for serum TIMP-2 levels, a significant decrease was found in transient responders and non-responders (p<0.01). The ratios of serum MMP-2 to TIMP-1 levels were significantly higher in transient responders and non-responders than in sustained responders (p<0.001, respectively) even when HCV RNA levels were low in patients with HCV genome subtype 1b or when the HCV genome subtype was 2a or 2b. Sustained response was never found in type 1b patients with ratios of serum MMP-2 to TIMP-1 levels of over 6.0. In logistic multivariate regression analysis, the ratios of serum MMP-2 to TIMP-1 level (p=0.0001), HCV genome subtype (p=0.005) and serum TIMP-2 level (p=0.03) were the independent predictors for sustained response, while serum MMP-2 level (p=0.0006) was the only predictor for no response. CONCLUSIONS: Serum MMP-2 and TIMP-1 levels might be useful for estimating the degree of liver fibrosis. The ratio of serum MMP-2 to TIMP-1 levels may serve as a new predictor of interferon response in patients with chronic hepatitis C.


Subject(s)
Gelatinases/blood , Glycoproteins/blood , Hepatitis C/enzymology , Liver Cirrhosis/enzymology , Metalloendopeptidases/blood , Protease Inhibitors/blood , Alanine Transaminase/blood , Antibodies, Viral/immunology , Antiviral Agents/administration & dosage , Antiviral Agents/therapeutic use , Biomarkers/blood , Chronic Disease , Collagenases/blood , Female , Follow-Up Studies , Genome, Viral , Hepacivirus/genetics , Hepacivirus/immunology , Hepatitis C/pathology , Hepatitis C/therapy , Humans , Immunoenzyme Techniques , Injections, Intravenous , Interferon-beta/administration & dosage , Interferon-beta/therapeutic use , Liver Cirrhosis/pathology , Male , Matrix Metalloproteinase 1 , Matrix Metalloproteinase 2 , Middle Aged , Polymerase Chain Reaction , Proteins/metabolism , RNA, Viral/analysis , Tissue Inhibitor of Metalloproteinase-2 , Tissue Inhibitor of Metalloproteinases , Treatment Outcome
20.
Gastrointest Endosc ; 45(2): 168-75, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9041004

ABSTRACT

BACKGROUND: Disease stage in patients with chronic hepatitis C was assessed by both peritoneoscopy and histology and correlated with responses to interferon therapy. METHODS: The subjects were 105 patients with chronic hepatitis C treated with interferon who were classified into 28 sustained responders, 34 transient responders, and 43 nonresponders according to alanine aminotransferase normalization. The influence of various patient's characteristics on responses to interferon therapy was investigated by multivariate analysis. RESULTS: Patients were categorized into 21 patients who exhibited a "smooth liver" on peritoneoscopy and did not demonstrate histologic bridging fibrosis (group I) and 84 patients who exhibited a "granular" or "nodular liver" on peritoneoscopy and/or had histologic bridging fibrosis (group II). Multivariate analysis showed that genotype 2a/2b (p = .0002), low viremia (p = .0048), and early disease stage (group I) (p = .0290) were significant independent factors contributing to sustained response, and that early disease stage (group I) (p = .0010) and genotype 2a/2b (p = .0085) were those contributing to sustained or transient response. Neither peritoneoscopic nor histologic findings alone were a significant factor influencing responses to interferon therapy. CONCLUSION: Disease stage assessed by both peritoneoscopic and histologic findings may serve as a reliable marker for predicting responses to interferon therapy in chronic hepatitis C.


Subject(s)
Antiviral Agents/therapeutic use , Hepatitis C/drug therapy , Hepatitis C/pathology , Interferons/therapeutic use , Laparoscopy/methods , Adult , Aged , Antiviral Agents/administration & dosage , Biopsy, Needle , Chronic Disease , Evaluation Studies as Topic , Female , Hepatitis C/physiopathology , Humans , Interferons/administration & dosage , Liver/pathology , Logistic Models , Male , Middle Aged , Multivariate Analysis , Prognosis , Sensitivity and Specificity , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...